Vanguard Group Inc. Reduces Stock Holdings in Align Technology, Inc. $ALGN

Vanguard Group Inc. lessened its holdings in shares of Align Technology, Inc. (NASDAQ:ALGN) by 2.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,243,065 shares of the medical equipment provider’s stock after selling 198,527 shares during the period. Vanguard Group Inc. owned approximately 11.37% of Align Technology worth $1,560,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALGN. Rothschild Investment LLC grew its position in Align Technology by 140.3% during the 2nd quarter. Rothschild Investment LLC now owns 149 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 87 shares during the period. True Wealth Design LLC lifted its holdings in shares of Align Technology by 7,650.0% in the 2nd quarter. True Wealth Design LLC now owns 155 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 153 shares during the period. Cromwell Holdings LLC boosted its stake in shares of Align Technology by 2,900.0% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 174 shares during the last quarter. SVB Wealth LLC acquired a new stake in Align Technology during the first quarter worth about $36,000. Finally, Farther Finance Advisors LLC grew its holdings in Align Technology by 42.2% during the second quarter. Farther Finance Advisors LLC now owns 310 shares of the medical equipment provider’s stock worth $59,000 after acquiring an additional 92 shares during the period. 88.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on ALGN. Piper Sandler restated an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Align Technology in a research report on Thursday, October 30th. Zacks Research raised shares of Align Technology from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 30th. UBS Group lowered their price target on shares of Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Thursday, October 16th. Stifel Nicolaus set a $200.00 price target on shares of Align Technology in a research report on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of Align Technology from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Align Technology currently has an average rating of “Hold” and a consensus target price of $175.45.

Align Technology Stock Performance

Align Technology stock opened at $142.56 on Friday. The stock has a market capitalization of $10.23 billion, a P/E ratio of 27.63, a P/E/G ratio of 1.49 and a beta of 1.84. The company’s fifty day moving average price is $132.93 and its 200 day moving average price is $157.70. Align Technology, Inc. has a 1 year low of $122.00 and a 1 year high of $246.19.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.23. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The business had revenue of $995.69 million for the quarter, compared to the consensus estimate of $980.75 million. During the same period last year, the firm posted $2.35 earnings per share. The company’s revenue was up 1.8% compared to the same quarter last year. Align Technology has set its Q4 2025 guidance at EPS. Sell-side analysts predict that Align Technology, Inc. will post 7.98 EPS for the current year.

Align Technology announced that its board has approved a stock buyback program on Tuesday, August 5th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the medical equipment provider to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.